CYAD-101

CYAD-101 is a first-in-class, non-gene edited allogeneic chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of solid tumors. It utilizes a CAR based on the natural killer group 2D (NKG2D) receptor fused to CD3ζ and co-expresses a T-cell receptor (TCR) inhibitory molecule (TIM), which reduces the risk of graft-versus-host disease by inhibiting endogenous TCR signaling without affecting CAR activity. The NKG2D CAR targets eight stress ligands overexpressed in various solid tumors, including metastatic colorectal cancer (mCRC). CYAD-101 is manufactured from healthy donor T cells and designed to be HLA-independent, allowing broad patient applicability. Its mechanism involves direct immunologic cytotoxicity against tumor cells expressing NKG2D ligands and modulation of the tumor microenvironment. Clinical studies demonstrated safety with no dose-limiting toxicities or GvHD and early signs of anti-tumor activity in mCRC patients; however, development for colorectal cancer has been discontinued following strategic review[2][6][9][10].

Other names

CYAD 101CYAD101CYAD-101TIM8-CYAD-01TIM-8-CYAD-01TIM 8-CYAD-01